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Abstract
OBJECTIVE: To investigated the effect and mecha-
nism of Fangjihuangqi Tang (FHT) on lower urinary
tract dysfunction induced by benign prostatic hy-
perplasia (BPH) in rats.
METHODS: Male rats were randomly divided into
seven groups: normal, model, finasteride (0.5 mg/
kg), terazosin (0.5 mg/kg), and FHT (10, 5, 2.5 g/kg).
Rats were administered testosterone (0.5 mg sc) for
6 weeks after orchiectomy, excluding the normal
group. All rats were intragastrically administered as-
signed drugs for 4 weeks from the third week. Uro-
dynamics were assessed in rats under anesthesia.
Serum dihydrotestosterone (DHT) and prostatic ac-
id phosphatase (PAP) were measured. The prostate
index (PI), bladder index (BI), and pathological de-
tection were evaluated.
RESULTS: In the model group, the PI, BI, serum
DHT, serum PAP, threshold pressure (TP), micturi-
tion pressure (MP), and residual urine volume (RV)
were significantly higher. Moreover, inter-micturi-
tion duration (IMD) was significantly lower and the
prostatic and bladder showed obvious pathologi-
cal changes. The IMD was significantly higher, while
BI, TP, MP, and RV were significantly lower and blad-
der pathological changes were alleviated in the
FHT (10, 5 g/kg), finasteride, and terazosin groups.
The PI, DHT, and PAP were significantly lower in the
finasteride group, but they did not change signifi-
cantly in the FHT (10, 5, 2.5 g/kg) and terazosin
groups.
CONCLUSION: FHT could relieve symptoms of low-
er urinary tract dysfunction in BPH rats but with no
apparent effect on reducing the volume of the en-
larged prostate itself.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Lower urinary tract symptoms (LUTS), secondary to
benign prostatic hyperplasia (BPH), are a common
problem in men and may significantly influence their
quality of life. LUTS may occur in up to 30% of men
older than 65 years. A population-based cross-sectional
survey on LUTS conducted in Austria showed that
64.6% of the male population aged 15-89 may suffer
from LUTS.1 The prevalence of LUTS in middle- and
old-aged males in China was close to that of Western
countries.2
Symptoms of LUTS include voiding (related to the
outlet), storage (related to the bladder), or a combina-
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tion of both.3,4 Notably, 52%-84% of patients have the
storage symptom subset of LUTS, which is also termed
overactive bladder (OAB) syndrome. OAB might have
a greater effect on quality of life compared to that of
the voiding symptoms of LUTS in both genders.5 Re-
sults from another study demonstrated that the preva-
lence of voiding symptoms among Austrian males was
35.5%, but the prevalence of storage symptoms reached
as high as 61.6%.1
Currently, medical therapy acts as an alternative to sur-
gery in a significant number of LUTS cases with
mild-to-moderate symptoms. Phytotherapeutic agents,α1-blockers, and 5α-reductase inhibitors are the three
main classes for the treatment of LUTS caused by
BPH.3,6,7 A revival of interest in phytotherapeutic
agents, both in Europe and North America, is a conse-
quence of patients' dissatisfaction with the adverse ef-
fects of medical alternatives.8,9
Fangjihuangqi Tang (FHT), a classical phytotherapeu-
tic formula from China, was first recorded in Jin Gui
Yao Lue, an ancient Chinese medical classic. FHT has
been the most popular prescription for treating edema
and dysuria in the Traditional Chinese Medical system
for more than 1800 years. It contains four herbs:
Fangji (Radix Stephaniae Tetrandrae) 12 g, Huangqi
(Radix Astragali Mongolici) 15 g, Baizhu (Rhizoma
Atractylodis Macrocephalae) 9 g, and Gancao (Radix
Glycyrrhizae) 6 g, with the function of improving dys-
uria and edema. Many studies have demonstrated that
FHT could deal with various clinical edemas.10 The
present experiment was conducted to explore if FHT
can alleviate BPH in rats, especially in improving the
symptoms of lower urinary tract dysfunction.
MATERIALS ANDMETHODS
Animals
One hundred and five 6-8 week-old male SD rats
weighing 150-200 g, supplied by the experimental ani-
mals center of Zhengzhou University of China, certifi-
cate: SCXK (Yu) 2005-0001, were housed under stan-
dard conditions of 22℃±3℃ with 40%-60% humidity
under a 12 h light-dark cycle, and were allowed free ac-
cess to tap water and food. Experimental protocols de-
scribed in this study were approved by the Ethics Re-
view Committee for Animal Experimentation of Anhui
University of Traditional Chinese Medicine and in
compliance with the guidelines of laboratory animal
care of NIH (NIH publication No. 85-23, revised
1985).
Drugs and reagents
The herbs of FHT were purchased from a local drug-
store specializing in herbs (Hefei, China). All plants
were authenticated by Prof. Jianli Zhou in the Chinese
medicinal plant identification laboratory of Anhui Uni-
versity of Traditional Chinese Medicine (Hefei, Chi-
na), and a voucher specimen are deposited in our labo-
ratory.
The materials were weighed according to the prescrip-
tion mentioned above. After water extraction, the solu-
tion was condensed to 2 g/mL, and stored at 4℃. The
dose of FHT was converted from the original prescrip-
tion.
Other experimental drugs and reagents were purchased
commercially, including finasteride tablets (Guang-
dong Yishu pharmacy Co. Ltd.; Guangdong, China;
batch No. 091018), terazosin hydrochloride tablets
(Shanghai Yapei pharmacy Co. Ltd.; Shanghai, China;
batch No. 090826), propionate testosterone injection
(Shanghai Tongyong pharmacy Co. Ltd.; Shanghai,
China; batch No. 090813), serum total acid phospha-
tase kit (Nanjing Jiancheng biological research insti-
tute; Nanjing, China; batch No. 091024), prostatic ac-
id phosphatase kit (Nanjing Jiancheng biological re-
search institute; Nanjing, China; batch No. 090817),
and dihydrotestosterone kit (Shanghai Xitang biologi-
cal technology Co. Ltd.; Shanghai, China; batch No.
090825).
Experimental model of BPH and drug treatment
The rats were divided into seven groups (n=15) accord-
ing to a randomized block design: normal, model, fin-
asteride (0.5 mg/kg), terazosin (0.5 mg/kg), and FHT
(10, 5, 2.5 g/kg). The experiments were carried out ac-
cording to established methods.11,12 Rats were castrated
while anaesthetized with chloral hydrate, excluding the
normal group, and then they were given penicillin
once a day for three days. A week later, the rats were ad-
ministrated testosterone (0.5 mg sc) once a day for 6
weeks. Each group was intragastrically administered
the corresponding drug once a day for 4 weeks, begin-
ning 2 weeks after making the rat model. The normal
and model groups were given an equal volume of vehi-
cle.
Determination of urodynamic parameter
The experiments were carried out in accordance with
our previously established methods.11 Briefly, 2 h after
final drug administration, urodynamic parameters in at
least in four micturition cycles of each rat were record-
ed by cystometry. Parameters including inter-micturi-
tion duration (IMD), threshold pressure (TP), micturi-
tion pressure (MP), and residual volume (RV) were re-
corded.
Measurement of serum dihydrotestosterone (DHT)
and prostatic acid phosphatase (PAP)
After the urodynamic parameter measurement, 5 mL
blood was taken from rats via the abdominal aorta.
Blood was centrifuged (3000 rpm) for 10 min at a low
temperature. The separated serum was kept at −20℃ .
Kits were used to detect the level of DHT, acid phos-
phatase (ACP), and non-prostatic acid phosphatase
(NPAP). Meanwhile, prostatic acid phosphatase (PAP)
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was calculated by the formula: PAP=ACP-NPAP.
PI, BI Determination and pathology examination
After completing the above examinations, prostates
and bladders were isolated from all rats and weighed.
Prostate index (PI) was defined as prostate weight/
body weight (mg/g). Bladder index (BI) was defined as
bladder weight/body weight (mg/g).
Afterwards, prostates and bladders were kept in 10%
formaldehyde solution and embedded in paraffin. Path-
ological changes were observed by light microscopy af-
ter hematoxylin-eosin (HE) staining.
Statistical analysis
Data are expressed as mean± standard deviation (SD).
All analyses were performed using DAS 2.0 statistical
software (prepared by the drug clinical research center
of Shanghai university of TCM). ANOVA was used in
comparisons followed by Tukey's multiple range tests.
P<0.05 was considered statistically significant.
RESULTS
General status and behavior observations
All animals maintained good health throughout the ex-
periments with no significant weight loss. During cys-
tometric measurement, one rat in both the model and
terazosin groups died, possibly due to anesthesia intol-
erance.
Effects of FHT on urodynamic parameter in BPH
rats
Compared with the normal group, the TP, MP, and RV
were significantly higher, while IMD was significantly
lower in the model group, indicating that the rats'
emiction function was influenced by BPH. Compared
with the model group, the IMD was significantly high-
er, while TP and MP were significantly lower in the
FHT (10, 5 g/kg), finasteride, and terazosin groups.
This indicated that FHT could effectively improve fre-
quent micturition and reduce the intravesical pres-
sure in BPH rats. The RV was significantly decreased
in FHT (10 g/kg), finasteride and terazosin groups
(Table 1).
Effects of FHT on serum DHT and PAP in BPH rats
Compared with normal group, the DHT, ACP, and
PAP were significantly higher in model group. The
above variables were obviously lower in the finasteride
group, but they had no significant changes in the FHT
Group
Normal
Model
Finasteride
Terazosin
FHT
n
15
14
15
14
15
15
15
Dose (g/kg)
-
-
0.0005
0.0005
10
5
2.5
IMD (s)
869.10±124.84
440.93±93.60a
602.21±109.20b
594.01±110.06b
591.81±124.65b
570.04±125.14b
533.31±98.00c
TP (mm Hg)
30.41±6.59
41.33±7.50a
33.08±7.84b
33.50±6.28b
34.09±5.62b
35.40±5.43c
38.08±8.66
MP (mm Hg)
37.54±7.84
47.26±8.47a
37.92±8.54b
39.34±8.01c
39.21±6.46b
40.87±7.11c
45.49±9.21
RV (mL)
0.16±0.06
0.47±0.10a
0.34±0.11b
0.35±0.12b
0.37±0.13c
0.39±0.12
0.43±0.10
Table 1 Effects of FHT on urodynamic parameters in BPH rats
Notes: FHT: Fangjihuangqi Tang; BPH: benign prostatic hyperplasia; IMD: inter-micturition duration; TP: threshold pressure; MP: mic-
turition pressure; RV: residual volume. The dose of FHT was converted from the original prescription. Compared with normal group, aP<
0.01; compared with model group, bP<0.01, cP<0.05.
Group
Normal
Model
Finasteride
Terazosin
FHT
n
15
14
15
14
15
15
15
Dose (g/kg)
-
-
0.0005
0.0005
10
5
2.5
DHT (ng/L)
6.1±1.8
15.8±3.2a
12.0±2.4b
14.7±2.6
14.8±3.7
15.0±3.8
14.7±2.8
ACP (U/L)
24.2±5.1
36.6±5.0a
28.6±4.4b
33.0±7.2
33.6±6.4
32.3±5.7
34.3±5.5
NPAP (U/L)
11.1±2.4
13.7±3.4
11.9±2.4
12.3±2.4
12.3±2.1
12.3±2.9
12.2±3.0
PAP (U/L)
13.1±4.5
23.0±5.0a
16.8±5.3b
20.8±8.0
21.3±6.0
20.0±5.9
22.0±4.9
Table 2 Effects of FHT on serum DHT and PAP in BPH rats
Notes: FHT: Fangjihuangqi Tang; DHT: dihydrotestosterone; ACP: acid phosphatase; NPAP: non-prostatic acid phosphatase; PAP: pros-
tatic acid phosphatase. The dose of FHT was converted from the original prescription. Compared with normal group, aP<0.01; compared
with model group, bP<0.01.
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Figure 1 Effects of FHT on histopathology of the prostate in BPH rats (HE stain, ×200)
A: normal, simple epithelium, glandular cavities regular and flat; B: model, glandular cavities expanded in a zigzag, multiple epi-
thelium, mesenchyme increased obviously; C: finasteride, epithelium thinner, little secretion and mesenchyme in the cavities; D:
terazosin, glandular cavities expanded, multiple epithelium, mesenchyme increased obviously; E: FHT (10 g/kg), glandular cavi-
ties expanded, multiple epithelium, mesenchyme increased obviously; F: FHT (5 g/kg), glandular cavities expanded, multiple epi-
thelium, mesenchyme increased obviously; G: FHT (2.5 g/kg), glandular cavities expanded, multiple epithelium, mesenchyme in-
creased obviously. FHT: Fangjihuangqi Tang; HE: hematein and eosin.
(10, 5, 2.5 g/kg) and terazosin groups (Table 2).
Effects of FHT on PI and BI in BPH rats
Compared with the normal group, the weight of the
prostates and bladders, PI and BI were all significantly
higher in the model group. The weight of the prostates
and PI were significantly lower in the finasteride
group, while the weight of the bladders and BI were
significantly lower in the FHT (10 g/kg) and terazosin
groups (Table 3).
Effects of FHT on histopathology of the prostate and
bladder in BPH rats
In the normal group, the prostatic epithelium was com-
posed of simple epithelium, the glandular cavities were
regular and flat with little secretion and mesenchyme,
and the size and shape of cell nucleuses were consis-
tent. In the model group, the prostates proliferated ob-
viously, the glandular cavities expanded in a zigzag
with the drape and incrassated gland extruding, and
the prostatic epithelium increased to multiple layers
with the secretion and mesenchyme increased obvious-
ly. In the finasteride group, the prostatic hyperplasia
was obviously alleviated, with thinner epithelium.
Meanwhile, there were relatively fewer secretions and
mesenchyme in the cavities. The prostate hyperplasia
conditions in the FHT (10, 5, 2.5 g/kg) and terazosin
groups were similar to the model group (Figure 1).
The detrusor cells of the bladder tended to be long and
fusiform, arrayed in parallel, and well-distributed, with
little secretion and mesenchyme in the normal group.
In the model group, the detrusor cells were irregularly
shaped and arrayed disorderedly with the mesenchyme
increased obviously. The sizes of the detrusor cells were
relatively consistent and well-distributed in the finaste-
ride, terazosin, and FHT (10 g/kg) groups. Though
the detrusor cells in the FHT (5, 2.5 g/kg) group were
also relatively well-distributed, the mesenchyme had
obvious hyperplasia (Figure 2).
DISCUSSION
The common etiology of male LUTS is BPH. Similar-
ly, most bladder outflow obstruction is caused by be-
Table 3 Effects of FHT on PI and BI in BPH rats
Group
Normal
Model
Finasteride
Terazosin
FHT
n
15
14
15
14
15
15
15
Dose (g/kg)
-
-
0.0005
0.0005
10
5
2.5
PW (mg)
404.41±82.86
601.51±195.67a
426.52±124.78b
587.47±113.52
592.82±193.61
583.79±144.67
595.31±118.30
PI (mg/g)
1.26±0.32
1.83±0.51a
1.28±0.29b
1.77±0.33
1.78±0.47
1.73±0.35
1.74±0.40
BW (mg)
252.31±39.45
472.82±134.01a
466.42±137.68
380.51±98.76c
387.32±81.31c
469.38±118.71
469.13±124.27
BI (mg/g)
0.79±0.17
1.44±0.31a
1.40±0.33
1.14±0.26c
1.18±0.22c
1.44±0.46
1.38±0.42
Notes: FHT: Fangjihuangqi Tang; PW: prostate weight; PI: prostate index; BW: bladder weight; BI: bladder index. The dose of FHT was
converted from the original prescription. Compared with normal group, aP<0.01; compared with model group, cP<0.05, bP<0.01.
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nign prostatic enlargement (BPE). BPE may induce
bladder outlet obstruction (BOO) and may progress to
LUTS (including BOO and OAB symptoms).3 There
are two principal mechanisms involved in the develop-
ment of BOO, mechanical obstruction due to in-
creased volume of the prostate and functional obstruc-
tion due to increased tone of the prostatic smooth mus-
cle. OAB induced by BOO may either manifest as de-
trusor overactivity during the filling phase or detrusor
underactivity during the voiding phase, or a combina-
tion of both.13 The increase in strain caused by the ob-
struction can induce overexpansion of the bladder,
which leads to ischemia, anoxia, and overactive blad-
der. One study indicated that chronic ischemia occurs
in the vesicle neck and prostate in older LUTS pa-
tients.14
Tatemichi et al 12 demonstrated a significantly increased
frequency of non-voiding bladder contraction in a rat
model of BPH induced by androgen in combination
with estrogen. They suggested that estrogen might
have a role in stimulating micturition.
Increased frequency of micturition was found to be
higher in the combination treatment group compared
with the androgen group. Maggi et al 15 compared the
urodynamic characteristics of the testosterone-induced
BPH rat model to the model developed by urethral li-
gation in female rats. They reported that high frequen-
cy rhythmic contractile activity occurred in the testos-
terone-treated rat.
In the present study, IMD was significantly decreased
while TP, MP, RV, PI, and BI increased in the model
group. The levels of serum DHT and PAP were also in-
creased. The glandular epithelium cells were columnar
or high columnar pathologically. The cavities expanded
obviously with secretion retention and hyperplasia of
the mesenchyme in different levels. This indicated that
the model rats had hypertrophic prostates, which could
lead to lower urinary tract dysfunction.
Unlike the 5α-reductase inhibitor finasteride, FHT has
no obvious effect on serum DHT and PAP in rats.
Therefore, FHT may have no direct inhibitory effect
on 5α-reductase in BPH rats. Similar to the α1-blocker
terazosin, FHT reduced BI, TP, MP, and RV signifi-
cantly, as well as dose-dependently prolonged IMD in
BPH rats.
Cumulative evidence shows that the principal mecha-
nism for the activation of the detrusor is involved in
the entry of extracellular calcium ions through dihydro-
pyridine-sensitive calcium channels and the mobiliza-
tion of intracellular calcium ions.16,17 Rud et al 18,19 and
we found clinically that L-type Ca2 + channel blockers
nifedipine or amlodipine could recover unstable blad-
ders in women or alleviate LUTS in men.
It is plausible that FHT may possess the capability for
the treatment of lower urinary tract dysfunction. Tet-
randrine, which is extracted from one of key compo-
nents of FHT, namely Fangji (Radix Stephaniae Tetran-
drae), was found to be a kind of calcium channel block-
er. Fangji could dose-dependently restrain the contrac-
tion of normal and hypertrophic rat bladder activated
by KCl, improve morphological changes of hypertro-
phic rat bladder, and inhibit the hyperplasia of bladder
collagen fibrils.20,21 We speculate that one of the mecha-
nisms of FHT might be associated with the restriction
of the internal flow of Ca2 + , therefore relaxing the
smooth muscles of the bladder. However, further stud-
ies need to be conducted to identify the mechanism.
Previous research has shown that, astragaloside, the
main active ingredient of Huangqi (Radix Astragali
Mongolici) in FHT can ease the tension of the internal
sphincter to help expanding and opening the urethra.22
The potential mechanism underling the above effect of
astragaloside is not clear and needs to be studied fur-
ther.
In conclusion, our findings indicate that FHT may im-
prove lower urinary tract dysfunction in BPH rats by
regulating smooth muscles in the bladder and urethra
rather than reducing the volume of the enlarged pros-
DCBA
E F G
Figure 2 Effect of FHT on histopathology of the bladder in BPH rats (HE stain, ×200)
A: normal, cells arrayed in parallel and well-distributed; B: model, cells were various shapes, disorder array, and the mesenchyme
increased; C: finasteride, cells were well-distributed relatively, the mesenchyme reduced; D: terazosin, cells were well-distributed
relatively, the mesenchyme reduced; E: FHT (10 g/kg), cells were well-distributed relatively, the mesenchyme reduced; F: FHT
(5 g/kg), cells were well-distributed relatively, but the mesenchyme had obvious hyperplasia; G: FHT (2.5 g/kg), cells were
well-distributed relatively, but the mesenchyme had obvious hyperplasia. FHT: Fangjihuangqi Tang; HE: hematein and eosin.
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tate. The exact active ingredients and mechanisms of
FHT need to be explored in the future.
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